
Kevin E Weddington
Examiner (ID: 109, Phone: (571)272-0587 , Office: P/1629 )
| Most Active Art Unit | 1614 |
| Art Unit(s) | 1629, 2899, 1614, 1205 |
| Total Applications | 3386 |
| Issued Applications | 2180 |
| Pending Applications | 434 |
| Abandoned Applications | 815 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18310598
[patent_doc_number] => 20230114498
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => COMPOSITION AND METHOD FOR TREATING DERMATOLOGICAL DISORDERS USING RETINAMIDES
[patent_app_type] => utility
[patent_app_number] => 17/787065
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14137
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17787065
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/787065 | COMPOSITION AND METHOD FOR TREATING DERMATOLOGICAL DISORDERS USING RETINAMIDES | Dec 17, 2020 | Pending |
Array
(
[id] => 16748756
[patent_doc_number] => 20210100765
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => METHODS OF TREATING MIXED DYSLIPIDEMIA
[patent_app_type] => utility
[patent_app_number] => 17/127398
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23779
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17127398
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/127398 | METHODS OF TREATING MIXED DYSLIPIDEMIA | Dec 17, 2020 | Abandoned |
Array
(
[id] => 18223752
[patent_doc_number] => 20230062746
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => A PHARMACEUTICAL COMPOSITION OF A PYRAZOLE COMPOUND DISPERSED IN A POLYMER MATRIX
[patent_app_type] => utility
[patent_app_number] => 17/785665
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4508
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17785665
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/785665 | A PHARMACEUTICAL COMPOSITION OF A PYRAZOLE COMPOUND DISPERSED IN A POLYMER MATRIX | Dec 17, 2020 | Pending |
Array
(
[id] => 16726438
[patent_doc_number] => 20210093585
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE
[patent_app_type] => utility
[patent_app_number] => 17/121547
[patent_app_country] => US
[patent_app_date] => 2020-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18155
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17121547
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/121547 | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride | Dec 13, 2020 | Issued |
Array
(
[id] => 16726473
[patent_doc_number] => 20210093620
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer
[patent_app_type] => utility
[patent_app_number] => 17/118033
[patent_app_country] => US
[patent_app_date] => 2020-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20138
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17118033
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/118033 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | Dec 9, 2020 | Abandoned |
Array
(
[id] => 18139750
[patent_doc_number] => 20230013586
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/782440
[patent_app_country] => US
[patent_app_date] => 2020-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18608
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782440
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/782440 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | Dec 3, 2020 | Pending |
Array
(
[id] => 16710294
[patent_doc_number] => 20210077441
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases
[patent_app_type] => utility
[patent_app_number] => 17/107724
[patent_app_country] => US
[patent_app_date] => 2020-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37196
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17107724
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/107724 | Compositions and methods for treating chronic inflammation and inflammatory diseases | Nov 29, 2020 | Issued |
Array
(
[id] => 18109520
[patent_doc_number] => 20230002400
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => AMORPHOUS FORM OF NITROGEN-CONTAINING TRICYCLIC COMPOUND AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/779197
[patent_app_country] => US
[patent_app_date] => 2020-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5684
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779197
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/779197 | AMORPHOUS FORM OF NITROGEN-CONTAINING TRICYCLIC COMPOUND AND USE THEREOF | Nov 26, 2020 | Abandoned |
Array
(
[id] => 18915779
[patent_doc_number] => 11878045
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-23
[patent_title] => Inducing cell death by hyperactivation of motility networks
[patent_app_type] => utility
[patent_app_number] => 17/106000
[patent_app_country] => US
[patent_app_date] => 2020-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 16
[patent_no_of_words] => 6889
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17106000
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/106000 | Inducing cell death by hyperactivation of motility networks | Nov 26, 2020 | Issued |
Array
(
[id] => 16686710
[patent_doc_number] => 20210069185
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => USE OF FLIBANSERIN IN THE TREATMENT OF OBESITY
[patent_app_type] => utility
[patent_app_number] => 17/101961
[patent_app_country] => US
[patent_app_date] => 2020-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5650
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17101961
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/101961 | USE OF FLIBANSERIN IN THE TREATMENT OF OBESITY | Nov 22, 2020 | Abandoned |
Array
(
[id] => 18404498
[patent_doc_number] => 20230165849
[patent_country] => US
[patent_kind] => A2
[patent_issue_date] => 2023-06-01
[patent_title] => USE OF PRIDOPIDINE FOR TREATING RETT SYNDROME
[patent_app_type] => utility
[patent_app_number] => 16/952123
[patent_app_country] => US
[patent_app_date] => 2020-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11442
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16952123
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/952123 | Use of pridopidine for treating rett syndrome | Nov 18, 2020 | Issued |
Array
(
[id] => 18404498
[patent_doc_number] => 20230165849
[patent_country] => US
[patent_kind] => A2
[patent_issue_date] => 2023-06-01
[patent_title] => USE OF PRIDOPIDINE FOR TREATING RETT SYNDROME
[patent_app_type] => utility
[patent_app_number] => 16/952123
[patent_app_country] => US
[patent_app_date] => 2020-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11442
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16952123
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/952123 | Use of pridopidine for treating rett syndrome | Nov 18, 2020 | Issued |
Array
(
[id] => 16711869
[patent_doc_number] => 20210079016
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => AMORPHOUS SOLID FORM OF A BET PROTEIN INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 16/952915
[patent_app_country] => US
[patent_app_date] => 2020-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12861
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16952915
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/952915 | AMORPHOUS SOLID FORM OF A BET PROTEIN INHIBITOR | Nov 18, 2020 | Abandoned |
Array
(
[id] => 16686685
[patent_doc_number] => 20210069160
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => DOSAGE REGIMEN FOR PICOTAMIDE FOR THE USE IN MIGRAINE
[patent_app_type] => utility
[patent_app_number] => 16/949866
[patent_app_country] => US
[patent_app_date] => 2020-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8347
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16949866
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/949866 | Dosage regimen for picotamide for the use in migraine | Nov 17, 2020 | Issued |
Array
(
[id] => 20156937
[patent_doc_number] => 12383535
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-12
[patent_title] => Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor
[patent_app_type] => utility
[patent_app_number] => 17/623882
[patent_app_country] => US
[patent_app_date] => 2020-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 2099
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17623882
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/623882 | Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor | Nov 15, 2020 | Issued |
Array
(
[id] => 18192926
[patent_doc_number] => 20230046445
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ss-CELL PATHOGENESIS AND TREATING DIABETES
[patent_app_type] => utility
[patent_app_number] => 17/780482
[patent_app_country] => US
[patent_app_date] => 2020-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17998
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780482
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/780482 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ss-CELL PATHOGENESIS AND TREATING DIABETES | Nov 14, 2020 | Pending |
Array
(
[id] => 18091237
[patent_doc_number] => 20220409578
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF RADIATION DERMATITIS AND OTHER SKIN DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/776707
[patent_app_country] => US
[patent_app_date] => 2020-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11948
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17776707
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/776707 | FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF RADIATION DERMATITIS AND OTHER SKIN DISORDERS | Nov 12, 2020 | Pending |
Array
(
[id] => 16655952
[patent_doc_number] => 20210052588
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => Methods Of Treating Depression Using Orexin-2 Receptor Antagonists
[patent_app_type] => utility
[patent_app_number] => 17/092725
[patent_app_country] => US
[patent_app_date] => 2020-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11993
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17092725
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/092725 | Methods of treating depression using orexin-2 receptor antagonists | Nov 8, 2020 | Issued |
Array
(
[id] => 18075800
[patent_doc_number] => 20220401412
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => METHODS FOR PALMAR OR PLANTAR ADMINISTRATION OF PHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/774850
[patent_app_country] => US
[patent_app_date] => 2020-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8854
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17774850
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/774850 | METHODS FOR PALMAR OR PLANTAR ADMINISTRATION OF PHARMACEUTICAL COMPOSITIONS | Nov 3, 2020 | Pending |
Array
(
[id] => 16655899
[patent_doc_number] => 20210052535
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY
[patent_app_type] => utility
[patent_app_number] => 17/086165
[patent_app_country] => US
[patent_app_date] => 2020-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39123
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17086165
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/086165 | Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity | Oct 29, 2020 | Issued |